ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 717

Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative

Lesley Ann Saketkoo1, Reuben Escorpizo2, Kevin J. Keen3, Kim Fligelstone4 and Oliver Distler5, 1LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 2ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications in Germany (DIMDI), Nottwil, Switzerland, 3Mathematics and Statistics, University of Northern British Columbia, Prince George, BC, Canada, 4Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, 5Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Disability, Economics, functional status, outcome measures and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic Sclerosis (SSc) affects multiple organs with complex combinations of disability. Skin fibrosis, ischemic pain, ulceration, arthritis, joint contractures, myopathy and cardiopulmonary, renal as well as gastrointestinal involvement affect emotional, social and physical functioning.

International Classification of Functioning, Disability, and Health (ICF), introduced by the World Health Organization (WHO), is a universal framework that describes the disabilities associate with a health condition in terms of the bio-psycho-social model with consideration of environmental and personal factors.

Methods:

Comprehensive literature review identified all validated outcome measures in SSc.   Five instruments were selected to represent the broadest range of SSc manifestations (OD, LAS), deconstructed to concepts and linked separately by 2 health professionals familiar with updated ICF linkage rules (RE, LAS). Inter-reviewer agreement was analyzed (KK).  Remaining instruments were deconstructed and linked. Five formal meetings with 27 patients (4 males) and 24 SSc specialists (physicians, therapists and nurses) from 16 countries provided data which were deconstructed, confirmed by participants and then linked to the ICF.

Results:

27 validated instruments were identified. 5 validated SSc instruments were linked to ICF codes  and tested inter-linker agreement. The proportion of agreement ranged from 0.8611 (95% CI: 0.7500, 0.9444) to 0.9647 (0.9175, 1.000) (Table 1) with the overall proportion of agreement 0.9359 (0.9172, 0.9506). 228 and 618 categories were linked in instrument and group data respectively. All instrument linkages were captured within the expert group data collection (Table 2).

Conclusion:

SSc is the most complex disease linked to the ICF. Important challenges exist in ICF Core Set development for SSc. Occurrences in the data suggest ICF level of specificity was insufficient to describe the SSc experience, e.g. Raynaud’s and specific aspects of pain. 618 linkages are unusually high for ICF item collection, SSc is likely to require the development of an advanced ICF Core Set model to accommodate its complexity and ensure utility.

Further face, content and construct validation strategies with item reduction are now underway. Very importantly, the weight of these results implies that the global, regional and personal impact of SSc across cultures, age and socioeconomic status is likely to be severely under-estimated. Efforts to establish fair assessment for use in policy making and provision of services and funding are essential towards optimal health and functioning in SSc.

 

Table 1. Point and interval estimates of proportion of agreement with and without correction for chance.

 

Proportion of Agreement

Proportion of Agreement

Corrected for Chance

 

Questionnaire

No. of Concepts

No. of

ICF Codes

Estimate

Lower

Limit

Upper

Limit

Estimate

Lower

Limit

Upper

Limit

 

HAMIS

  9

  4

0.8611

0.7500

0.9444

0.7097

0.5291

0.8835

 

mRSS

17

  5

0.9647

0.9176

1.0000

0.8964

0.7631

1.0000

 

RCS

  7

10

0.9082

0.8367

0.9388

0.6736

0.3879

0.7726

 

SHAQ

  7

11

0.9048

0.8477

0.9524

0.6650

0.4848

0.8279

 

SSc GIT

25

16

0.9506

0.9318

0.9718

0.6599

0.5306

0.7912

 

Overall

65

0.9359

0.9172

0.9506

0.7230

0.6453

0.7797

 

HAMIS: Hand Mobility in Scleroderma Test, mRSS: Modified Rodnan Skin Score, RCS: Raynaud Condition Score,  SHAQ: Scleroderma Health Assessment Questionnaire, SSc GIT: SSc Gastrointestinal Tract Instrument

 

Table 2. ICF Linkage of Validated SSc Instruments and Expert Data

ICF Domain

Patient & Medical Experts

Validated Instruments

Common to Both

Total

Identified

Body Structure

126

16

16

126

Body Function

149

108

107

150

Activities and Participation

265

96

96

265

Environmental Factors

78

9

9

78

Total

618

229

228

619

 


Disclosure:

L. A. Saketkoo,

United Therapeutics,

2,

Actelion Pharmaceuticals US,

2;

R. Escorpizo,
None;

K. J. Keen,

Merck, Canada,

9;

K. Fligelstone,
None;

O. Distler,

Actelion, Pfizer, Boehringer-Ingelheim, Bayer, Roche, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, medac, Biovitrium, Novartis and Active Biotec,

2,

Actelion, Pfizer, Boehringer-Ingelheim, Bayer, Roche, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, medac, Biovitrium, Novartis and Active Biotec,

5,

Actelion, Pfizer and Ergonex,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/results-from-a-multi-tiered-item-collection-on-linking-systemic-sclerosis-to-the-international-classification-of-functioning-disability-and-health-a-eular-scleroderma-trials-and-research-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology